Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43


Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, D'Rozario JM, Dimopoulos MA, Martínez S, Extremera S, Kahatt C, Alfaro V, Carella AM, Meuleman N, Hájek R, Symeonidis A, Min CK, Cannell P, Ludwig H, Sonneveld P, Mateos MV.

Ann Hematol. 2019 Jun 25. doi: 10.1007/s00277-019-03739-2. [Epub ahead of print]


Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3.

Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G.

Toxicol Rep. 2019 Apr 19;6:369-379. doi: 10.1016/j.toxrep.2019.04.006. eCollection 2019.


Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma.

Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G.

Br J Haematol. 2019 May;185(3):588-592. doi: 10.1111/bjh.15569. Epub 2018 Sep 26. No abstract available.


RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.

Chapman MA, Sive J, Ambrose J, Roddie C, Counsell N, Lach A, Abbasian M, Popat R, Cavenagh JD, Oakervee H, Streetly MJ, Schey S, Koh M, Willis F, Virchis AE, Crowe J, Quinn MF, Cook G, Crawley CR, Pratt G, Cook M, Braganza N, Adedayo T, Smith P, Clifton-Hadley L, Owen RG, Sonneveld P, Keats JJ, Herrero J, Yong K.

Blood. 2018 Nov 15;132(20):2154-2165. doi: 10.1182/blood-2018-05-849893. Epub 2018 Sep 4.


Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial).

Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E, Cavenagh J; Myeloma UK Early Phase Clinical Trial Network.

Br J Haematol. 2019 May;185(3):573-578. doi: 10.1111/bjh.15551. Epub 2018 Aug 20. No abstract available.


Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.

Davies JK, Hassan S, Sarker SJ, Besley C, Oakervee H, Smith M, Taussig D, Gribben JG, Cavenagh JD.

Br J Haematol. 2018 Feb;180(3):346-355. doi: 10.1111/bjh.14980. Epub 2017 Oct 26.


A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

Cavenagh J, Oakervee H, Baetiong-Caguioa P, Davies F, Gharibo M, Rabin N, Kurman M, Novak B, Shiraishi N, Nakashima D, Akinaga S, Yong K.

Br J Cancer. 2017 Oct 24;117(9):1295-1302. doi: 10.1038/bjc.2017.302. Epub 2017 Sep 5.


Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.

Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E, Cavenagh J; Myeloma UK Early Phase Clinical Trial Network.

Lancet Haematol. 2016 Dec;3(12):e572-e580. doi: 10.1016/S2352-3026(16)30165-X. Epub 2016 Nov 12.


Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.

Yong K, Cavet J, Johnson P, Morgan G, Williams C, Nakashima D, Akinaga S, Oakervee H, Cavenagh J.

Br J Cancer. 2016 Jan 12;114(1):7-13. doi: 10.1038/bjc.2015.422. Epub 2015 Dec 22.


Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators.

N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2.


Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation.

Miraki-Moud F, Anjos-Afonso F, Hodby KA, Griessinger E, Rosignoli G, Lillington D, Jia L, Davies JK, Cavenagh J, Smith M, Oakervee H, Agrawal S, Gribben JG, Bonnet D, Taussig DC.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13576-81. doi: 10.1073/pnas.1301891110. Epub 2013 Jul 30.


The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models.

Maharaj L, Marson CM, Middleton BJ, Rioja AS, Perry J, Oakervee H, Cavenagh J, Joel SP, Popat R.

Br J Haematol. 2013 Oct;163(1):135-9. doi: 10.1111/bjh.12456. Epub 2013 Jul 9. No abstract available.


Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion.

Davies JK, Taussig D, Oakervee H, Smith M, Agrawal S, Cavenagh JD, Gribben JG.

Br J Haematol. 2013 Aug;162(4):525-9. doi: 10.1111/bjh.12402. Epub 2013 May 29.


A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.

Popat R, Plesner T, Davies F, Cook G, Cook M, Elliott P, Jacobson E, Gumbleton T, Oakervee H, Cavenagh J.

Br J Haematol. 2013 Mar;160(5):714-7. doi: 10.1111/bjh.12154. Epub 2012 Dec 4. No abstract available.


Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma.

Popat R, Maharaj L, Oakervee H, Cavenagh J, Joel S.

Br J Haematol. 2013 Jan;160(1):111-4. doi: 10.1111/bjh.12089. Epub 2012 Oct 18. No abstract available.


T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.

Auer RL, MacDougall F, Oakervee HE, Taussig D, Davies JK, Syndercombe-Court D, Agrawal S, Cavenagh JD, Lister TA, Gribben JG.

Br J Haematol. 2012 Jun;157(5):580-5. doi: 10.1111/j.1365-2141.2012.09106.x. Epub 2012 Mar 26.


Bile acid malabsorption in patients with graft-versus-host disease of the gastrointestinal tract.

Joshi NM, Hassan S, Jasani P, Dixon S, Cavenagh JD, Oakervee HE, Smith M, Agrawal SA, Auer R, de Vos J, Langmead L, Rampton DS, Gribben JG, Taussig DC.

Br J Haematol. 2012 May;157(3):403-7. doi: 10.1111/j.1365-2141.2011.09014.x. Epub 2012 Jan 9. No abstract available.


Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD.

Dignan FL, Greenblatt D, Cox M, Cavenagh J, Oakervee H, Apperley JF, Fielding AK, Pagliuca A, Mufti G, Raj K, Marks DI, Amrolia P, Peniket A, Medd P, Potter MN, Shaw BE, Scarisbrick JJ.

Bone Marrow Transplant. 2012 Jun;47(6):824-30. doi: 10.1038/bmt.2011.186. Epub 2011 Sep 19.


Frequency of leukemic initiating cells does not depend on the xenotransplantation model used.

Vargaftig J, Taussig DC, Griessinger E, Anjos-Afonso F, Lister TA, Cavenagh J, Oakervee H, Gribben J, Bonnet D.

Leukemia. 2012 Apr;26(4):858-60. doi: 10.1038/leu.2011.250. Epub 2011 Sep 16. No abstract available.


Differential and tumor-specific expression of CD160 in B-cell malignancies.

Farren TW, Giustiniani J, Liu FT, Tsitsikas DA, Macey MG, Cavenagh JD, Oakervee HE, Taussig D, Newland AC, Calaminici M, Bensussan A, Jenner M, Gribben JG, Agrawal SG.

Blood. 2011 Aug 25;118(8):2174-83. doi: 10.1182/blood-2011-02-334326. Epub 2011 Jun 28.


Nosocomial transmission of parainfluenza 3 virus in hematological patients characterized by molecular epidemiology.

Lee AV, Bibby DF, Oakervee H, Rohatiner A, Ushiro-Lumb I, Clark DA, Mattes FM.

Transpl Infect Dis. 2011 Aug;13(4):433-7. doi: 10.1111/j.1399-3062.2011.00603.x. Epub 2011 Apr 5.


Re-transplantation after bortezomib-based therapy.

Morris C, Cook G, Streetly M, Kettle P, Drake M, Quinn M, Cavet J, Tighe J, Kazmi M, Ashcroft J, Cook M, Snowden J, Olujohungbe A, Marshall S, Conn J, Oakervee H, Popat R, Cavenagh J.

Br J Haematol. 2011 Jun;153(5):666-8. doi: 10.1111/j.1365-2141.2010.08521.x. Epub 2011 Jan 31. No abstract available.


Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.

Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, Lister TA, Gribben JG, Bonnet D.

Blood. 2010 Mar 11;115(10):1976-84. doi: 10.1182/blood-2009-02-206565. Epub 2010 Jan 6.


Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience.

Tsitsikas DA, Oakervee H, Cavenagh JD, Gribben J, Agrawal SG, Mattes FM.

Br J Haematol. 2009 Sep;146(5):574-6. doi: 10.1111/j.1365-2141.2009.07763.x. Epub 2009 Jun 15. No abstract available.


Patterns of recruitment into acute myeloid leukaemia (AML) 15 and outcome for young patients with AML at a single referral centre.

Stevens JM, Macdougall F, Jenner M, Oakervee H, Cavenagh J, Lister AT.

Br J Haematol. 2009 Apr;145(1):40-4. doi: 10.1111/j.1365-2141.2008.07561.x. Epub 2009 Feb 3.


Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.

Popat R, Oakervee H, Williams C, Cook M, Craddock C, Basu S, Singer C, Harding S, Foot N, Hallam S, Odeh L, Joel S, Cavenagh J.

Br J Haematol. 2009 Mar;144(6):887-94. doi: 10.1111/j.1365-2141.2008.07572.x. Epub 2009 Jan 12.


Resolution of cast nephropathy following free light chain removal by haemodialysis in a patient with multiple myeloma: a case report.

Basnayake K, Hutchison C, Kamel D, Sheaff M, Ashman N, Cook M, Oakervee H, Bradwell A, Cockwell P.

J Med Case Rep. 2008 Dec 9;2:380. doi: 10.1186/1752-1947-2-380.


Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.

Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, Lister TA, Gribben JG, Bonnet D.

Blood. 2008 Aug 1;112(3):568-75. doi: 10.1182/blood-2007-10-118331. Epub 2008 Jun 3.


Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.

Popat R, Oakervee HE, Hallam S, Curry N, Odeh L, Foot N, Esseltine DL, Drake M, Morris C, Cavenagh JD.

Br J Haematol. 2008 May;141(4):512-6. doi: 10.1111/j.1365-2141.2008.06997.x. Epub 2008 Mar 26.


Development of original donor cell leukemia after successful engraftment from a second donor.

Stevens JM, Syndercombe-Court D, Oakervee HE, McCloskey D, Jenner MJ, Gribben JG, Cavenagh JD.

Blood. 2007 Dec 15;110(13):4621-2. No abstract available.


Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy.

Sirohi B, Powles R, Cavanagh J, Oakervee H, Dyer P, Rintala T, Kulkarni S, Rudin C, Horton C, Treleaven J, Morgan G.

Hematology. 2007 Apr;12(2):113-5.


Posterior reversible encephalopathy syndrome following anti-lymphocyte globulin treatment for severe aplastic anaemia.

Greaves P, Oakervee H, Kon SS, Jones R, Farah N.

Br J Haematol. 2006 Aug;134(3):251. No abstract available.


Bortezomib for multiple myeloma.

Popat R, Joel S, Oakervee H, Cavenagh J.

Expert Opin Pharmacother. 2006 Jul;7(10):1337-46. Review.


Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease.

Davies JK, Taussig DC, Oakervee H, Davies AJ, Agrawal SG, Gribben JG, Lister TA, Cavenagh JD.

J Clin Oncol. 2006 May 10;24(14):e23-5. No abstract available.


Hepatitis-associated aplastic anaemia treated successfully with antilymphocyte globulin.

Bhattacharyya M, Oakervee H, Dalley C, Glynn M, Cavenagh J.

Clin Lab Haematol. 2005 Oct;27(5):331-3.


Guillain Barré syndrome precipitated by the use of antilymphocyte globulin in the treatment of severe aplastic anaemia.

Kaya B, Davies CE, Oakervee HE, Silver NC, Gawler J, Cavenagh JD.

J Clin Pathol. 2005 Sep;58(9):994-5.


PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.

Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD.

Br J Haematol. 2005 Jun;129(6):755-62.


Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care.

Gordon AC, Oakervee HE, Kaya B, Thomas JM, Barnett MJ, Rohatiner AZ, Lister TA, Cavenagh JD, Hinds CJ.

Anaesthesia. 2005 Apr;60(4):340-7.


Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting.

Taussig DC, Davies AJ, Cavenagh JD, Oakervee H, Syndercombe-Court D, Kelsey S, Amess JA, Rohatiner AZ, Lister TA, Barnett MJ.

J Clin Oncol. 2003 Aug 15;21(16):3060-5.


An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment.

Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW.

Leuk Res. 2003 Oct;27(10):909-14.


Thalidomide in multiple myeloma: current status and future prospects.

Cavenagh JD, Oakervee H; UK Myeloma Forum and the BCSH Haematology/Oncology Task Forces.

Br J Haematol. 2003 Jan;120(1):18-26. No abstract available.


A forgotten cause of abdominal pain.

Daoud RA, Oakervee HE, Bowley DM.

J R Army Med Corps. 1998 Feb;144(1):29-30. No abstract available.


Supplemental Content

Loading ...
Support Center